Welcome to the e-CCO Library!

P381: Factors predicting risk of colectomy in patients receiving first line steroid and second line biologic salvage therapy for Acute Severe Ulcerative Colitis
Year: 2022
Source: ECCO'22
Authors: Skinezes, Y.(1,2);Meir, Z.Y.(1,2);Abitbol, C.M.(1,2);Levartovsky, A.(1,2);Klang, E.(1,2);Kopylov, U.(1,2);Ben-Horin, S.(1,2);Ungar, B.(1,2);
Created: Friday, 11 February 2022, 3:52 PM
P381: Fatigue is an independent disease manifestation largely independent of chronicity, comorbidity and disease activity in patients with Inflammatory Bowel Disease
Year: 2021
Source: ECCO'21 Virtual
Authors: Risager Christensen, K.(1);Steenholdt, C.(1);Buhl, S.(1);Skougaard, M.(2);Brynskov, J.(1);Ainsworth, M.A.(3);Schjødt Jørgensen, T.(2);Kristensen, L.E.(2);
Created: Wednesday, 2 June 2021, 4:12 PM
P381: Infliximab induction regimes in steroid refractory acute severe colitis: a multi-centre retrospective cohort study with propensity score analysis
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

S. Sebastian*1,2, S. Myers1, N. Syed1, K. Argyriou3, G. Martin4, L. Los5, J. Fiske6, R. Ranjan7, B. Cooper8, N. Patel9, V. Goodoory10, F. Shaikh10, H. L. Ching11, N. Jayasooriya12, J. Brooks13, A. Dhar7, A. H. Shenoy8, J. Limdy6, J. Butterworth5, P. B. Allen4, S. Samuel3, G. Moran3, R. Shenderey10, G. Parkes12, A. Lobo11, S. Subramanian9, T. Raine14

Created: Friday, 22 February 2019, 9:41 AM
P381: Predictors of vedolizumab response to induction: Real-life experience
Year: 2018
Source: ECCO '18 Vienna
Authors:

A. Gutiérrez1,2*, L. Sempere1, M. Belvis3, J.M. Vázquez4, R. Laveda5, M. García6, F. Argüelles-Arias3, H. Pallarés4, L. Castro3, E. Gómez4, B. Maldonado3

Created: Thursday, 21 February 2019, 9:14 AM
P381: Ustekinumab trough levels are associated with sonographic transmural healing in Pediatric Inflammatory Bowel Disease
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Kellar, A.(1)*;Aronskyy, I.(1);Dubinsky, M.C.(1);Dolinger, M.T.(1);
Created: Friday, 14 July 2023, 11:05 AM
P382 Application of enhanced recovery after surgery in single-port laparoscopic partial small intestine resection in the treatment of Crohn’s disease
Year: 2020
Source:

ECCO'20 Vienna

Authors:

Y. LI, Z. Zhou, D. Yao, L. Zheng, Y. Duan, B. Liu, Y. Huang

Created: Thursday, 30 January 2020, 10:12 AM
P382: A panel of serum markers for early detection of endoscopic healing with infliximab in patients with ulcerative colitis
Year: 2017
Source: ECCO '17 Barcelona
Authors:

de Bruyn M.*1,2, Ringold R.3, Ferrante M.2,4, Van Assche G.2,4, Opdenakker G.1, Dukler A.3, Vermeire S.2,4

Created: Wednesday, 20 February 2019, 10:36 AM
P382: Combination therapy with TNF-inhibitors and immunomodulators are associated with shorter duration to first serious infection: the DEVELOP experience
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

J. Escher*1, B. Gold2, J. Izanec3, C. Busse4, Y. Wang5, S. Cucchiara6

Created: Friday, 22 February 2019, 9:41 AM
P382: Comparison of efficacy and safety of biosimilar infliximab to originator infliximab in children with inflammatory bowel disease
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

R. Muhammed*, L. Whyte, S. Protheroe, R. Bremner, W. Haller, T. Wong

Created: Friday, 22 February 2019, 9:49 AM
P382: CRP/albumin ratio: Predictive factor of the response to corticosteroids in acute severe colitis
Year: 2018
Source: ECCO '18 Vienna
Authors:

S. Jardak1*, M. Medhioub2, K. Agar2, L. Hamzaoui1,2,3, A. Khsiba2, M.M. Azouz2

Created: Thursday, 21 February 2019, 9:14 AM
P382: High anti-tumor necrosis factor alpha treatment trough concentrations are not associated with higher rate of adverse events in pediatric patients with inflammatory bowel disease
Year: 2021
Source: ECCO'21 Virtual
Authors: Zvuloni, M.(1);Matar, M.(2);Levi, R.(3);Shamir, R.(1,2);Assa, A.(2,4);
Created: Wednesday, 2 June 2021, 4:12 PM
P382: Serum Ustekinumab Concentrations are Associated with Improved Outcomes with the Magnetic Resonance Index of Activity for Crohn's Disease
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Chen, K.(1,2)*;Chen, J.(3);Smith, E.(1,2);Mathani, P.(1,2);Longman, R.(1,2);Lukin, D.(1,2);Scherl, E.(1,2);Battat, R.(1,2);
Created: Friday, 14 July 2023, 11:05 AM
P383 The level of intestinal inflammation and fibrosis in resection specimens after preoperative anti-tumour necrosis factor-α treatment in patients with Crohn’s disease: a comparative pilot study
Year: 2020
Source:

ECCO'20 Vienna

Authors:

J. Torle1, P. Dabir2, U. Korsgaard3, J.J. Christiansen3, N. Qvist4, A. El-Hussuna5

Created: Thursday, 30 January 2020, 10:12 AM
P383: Breast feeding practices differ between mothers with IBD and mothers without IBD
Year: 2018
Source: ECCO '18 Vienna
Authors:

C. Baker1, V. Nguyen2, S. Andriasak2, L. Ambrosio3, K.-A. Berga1, L. Dieleman3, B. Halloran3, K.I. Kroeker3, F. Peerani3, K. Wong3, V.W. Huang3*, R.N. Fedorak3

Created: Thursday, 21 February 2019, 9:14 AM
P383: Increasing treatment time on REMICADE® (infliximab) predicts subsequent long-term retention in stable infliximab inflammatory bowel disease patients in Canada
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Marshall J.K.*1,2, Marrache A.M.3, Ewara E.4

Created: Wednesday, 20 February 2019, 10:36 AM
P383: One-year experience with ustekinumab in therapy-refractory or -intolerant patients with ulcerative colitis
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

T. Ochsenkühn1, C. Tillack2, F. Schnitzler3, D. Szokodi2, S. Janelidze2

Created: Friday, 22 February 2019, 9:41 AM
P383: Real-life experience of the efficacy, safety and pharmacokinetic data of switching from intravenous to subcutaneous infliximab in inactive inflammatory bowel disease patients. Results from the ENEIDA registry.
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Iborra Colomino, M.I.(1)*;Garrido Marín, A.(1);Caballol Oliva, B.(2);Huguet Malavés, J.M.(3);Arias García, L.(4);Mesonero Gismero, F.(5);Fernández Prada, S.J.(6);Boscá Watts, M.M.(7);Ponferrada Díaz, Á.(8);Calvet Calvo, X.(9);Gutiérrez Casbas, A.(10); Ordás Jiménez, I.(2);Ruiz Sanchez, L.(3);Sicilia Aladren, B.(4);Garcia de la Filia, I.(5);Domènech Morral, E.(11);Nos Mateu, P.(1);
Created: Friday, 14 July 2023, 11:05 AM
P383: Relationship between histo-endoscopic mucosal healing and baseline characteristics in patients with moderately to severely active Ulcerative Colitis receiving filgotinib in the phase 2b/3 SELECTION study
Year: 2021
Source: ECCO'21 Virtual
Authors: Peyrin-Biroulet , L.(1);Loftus Jr , E.V.(2);Hibi , T.(3);Birchwood , C.(4);Yun , C.(4);Zhao , S.(4);Liu , X.(4);Rogler , G.(5);Danese , S.(6);Colombel , J.F.(7);Feagan , B.(8);
Created: Wednesday, 2 June 2021, 4:12 PM
P383: Short- and long-term outcomes of infliximab and calcineurin inhibitor treatment for steroid-refractory ulcerative colitis
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

S. Motoya*, M. Miyakawa, M. Nasuno, H. Tanaka

Created: Friday, 22 February 2019, 9:49 AM